Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML. Dvorak CC, et al. Among authors: pei q. Pediatr Blood Cancer. 2018 Jul;65(7):e27034. doi: 10.1002/pbc.27034. Epub 2018 Mar 12. Pediatr Blood Cancer. 2018. PMID: 29528181 Free PMC article. Clinical Trial.
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group.
Untanu RV, Back J, Appel B, Pei Q, Chen L, Buxton A, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL, Hutchison RE. Untanu RV, et al. Among authors: pei q. Pediatr Blood Cancer. 2018 Jan;65(1):10.1002/pbc.26753. doi: 10.1002/pbc.26753. Epub 2017 Aug 12. Pediatr Blood Cancer. 2018. PMID: 28802087 Free PMC article. Clinical Trial.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Buhtoiarov IN, Mba NI, Santos CDL, McCarten KM, Metzger ML, Pei Q, Bush R, Baker K, Kelly KM, Cole PD. Buhtoiarov IN, et al. Among authors: pei q. Pediatr Blood Cancer. 2022 Jun;69(6):e29649. doi: 10.1002/pbc.29649. Epub 2022 Mar 26. Pediatr Blood Cancer. 2022. PMID: 35338689 Free PMC article.
Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton AB, Bush R, Constine LS, Schwartz CL. Keller FG, et al. Among authors: pei q. Cancer. 2018 Aug 1;124(15):3210-3219. doi: 10.1002/cncr.31519. Epub 2018 May 8. Cancer. 2018. PMID: 29738613 Free PMC article. Clinical Trial.
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Cole PD, et al. Among authors: pei q. Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16. Lancet Oncol. 2018. PMID: 30122620 Free PMC article. Clinical Trial.
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
Milgrom SA, Kim J, Chirindel A, Kim J, Pei Q, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Hoppe BS, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY. Milgrom SA, et al. Among authors: pei q. Pediatr Blood Cancer. 2021 Sep;68(9):e29212. doi: 10.1002/pbc.29212. Epub 2021 Jul 10. Pediatr Blood Cancer. 2021. PMID: 34245210 Free PMC article.
622 results